Search | Clinical Trials Finder

Conditions: Moderate-to-severe Chronic Noncancer Pain
Interventions: Oxycodone extended-release; Drug
Lead sponsor: Egalet Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 39
States / cities: Huntsville, Alabama • Tucson, Arizona • Jacksonville, Florida + 35 more

Conditions: Healthy
Interventions: PF614, Oxycodone extended-release, Naltrexone Hydrochloride; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Opioid Users
Interventions: Capsule, PF-00345439, oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain
Interventions: Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Readiness to Discharge
Interventions: Peri-Articular Injection, Epidural Pathway (PCEA+FNB); Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthroplasty
Interventions: Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more

Conditions: Osteoarthritis of the Knee
Interventions: ARRY-371797, p38 inhibitor; oral, Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral, Placebo; oral; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Pinellas Park, Florida + 10 more

Conditions: Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions: Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pain, Postoperative, Spine Injuries and Disorders, Narcotic Use
Interventions: Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
Interventions: Oxycodone CR, Tapentadol (CG5503) ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more

Conditions: Opioid Use, Pain, Femoral Acetabular Impingement, Labral Tear, Glenoid
Interventions: Control Group Regimen, Opioid reduced regimen; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Baseline Epidemiologic Assessment
Interventions: MorphaBond ER, Comparator Drug; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: Not listed
Enrollment: 17,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Chronic Pain
Interventions: Extended Release Oxycodone, Immediate Release Oxycodone; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy
Interventions: ALO-02 (Oxycodone Naltrexone); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 84
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more

Conditions: Moderate-to-severe Chronic Low Back Pain
Interventions: Oxycodone extended-release, Placebo of oxycodone extended-release; Drug
Lead sponsor: Egalet Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Osteoarthritis, Low Back Pain
Interventions: COV795; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 42
States / cities: Tucson, Arizona • Anaheim, California • Buena Park, California + 33 more

Conditions: Opioid Abuse Nondependent
Interventions: PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone; Drug · Other
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post Operative Pain
Interventions: Norco 7.5mg/325, MNK155; Drug
Lead sponsor: Neil Singla; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions: Nucynta ER; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more

Conditions: Healthy Volunteers
Interventions: PF614, Naltrexone Hydrochloride, OxyContin; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Disorder of Knee
Interventions: Oxycodone; Drug
Lead sponsor: International Clinical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pain
Interventions: Oxycodone hydrochloride controlled-release tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Birmingham, Alabama • Paramount, California • Aurora, Colorado + 10 more

Conditions: Pharmacokinetics
Interventions: PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

Abuse Potential Study of PF-00345439

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Hip Arthroscopy Postoperative Opioid Demands

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

Open-Label Trial Comparing Oxycodone Medications

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain

Nasal Human Abuse Potential of PTI-821

A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)